These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20370621)

  • 21. Type III secretion machines: bacterial devices for protein delivery into host cells.
    Galán JE; Collmer A
    Science; 1999 May; 284(5418):1322-8. PubMed ID: 10334981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of efflux pump inhibitors to treat Gram-negative infections.
    Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
    Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections.
    Huwaitat R; McCloskey AP; Gilmore BF; Laverty G
    Future Microbiol; 2016 Jul; 11():955-72. PubMed ID: 27357521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insertion of the bacterial type III translocon: not your average needle stick.
    Coombes BK; Finlay BB
    Trends Microbiol; 2005 Mar; 13(3):92-5. PubMed ID: 15737725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacterial pathogenesis: the answer to virulence is in the pore.
    Gauthier A; Finlay BB
    Curr Biol; 2001 Apr; 11(7):R264-7. PubMed ID: 11413015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antivirulence therapy for animal production: filling an arsenal with novel weapons for sustainable disease control.
    Defoirdt T
    PLoS Pathog; 2013; 9(10):e1003603. PubMed ID: 24130477
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of a hospital-wide antibiotic restriction policy program on the resistance rates of nosocomial Gram-negative bacteria.
    Antoniadou A; Kanellakopoulou K; Kanellopoulou M; Polemis M; Koratzanis G; Papademetriou E; Poulakou G; Giannitsioti E; Souli M; Vatopoulos A; Giamarellou H
    Scand J Infect Dis; 2013 Jun; 45(6):438-45. PubMed ID: 23336730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Priming virulence factors for delivery into the host.
    Stebbins CE; Galán JE
    Nat Rev Mol Cell Biol; 2003 Sep; 4(9):738-43. PubMed ID: 14506477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad-spectrum quorum sensing and biofilm inhibition by green tea against gram-negative pathogenic bacteria: Deciphering the role of phytocompounds through molecular modelling.
    Qais FA; Khan MS; Ahmad I
    Microb Pathog; 2019 Jan; 126():379-392. PubMed ID: 30476580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VirB8: a conserved type IV secretion system assembly factor and drug target.
    Baron C
    Biochem Cell Biol; 2006 Dec; 84(6):890-9. PubMed ID: 17215876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type IV secretion: intercellular transfer of macromolecules by systems ancestrally related to conjugation machines.
    Christie PJ
    Mol Microbiol; 2001 Apr; 40(2):294-305. PubMed ID: 11309113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quorum quenching: role of nanoparticles as signal jammers in Gram-negative bacteria.
    Hayat S; Muzammil S; Shabana ; Aslam B; Siddique MH; Saqalein M; Nisar MA
    Future Microbiol; 2019 Jan; 14():61-72. PubMed ID: 30539663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bacterial secretion systems: their function and contribution to disease process].
    Abe A
    Kansenshogaku Zasshi; 2009 Mar; 83(2):94-100. PubMed ID: 19364035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-resistant gram-negative uropathogens: A review.
    Khoshnood S; Heidary M; Mirnejad R; Bahramian A; Sedighi M; Mirzaei H
    Biomed Pharmacother; 2017 Oct; 94():982-994. PubMed ID: 28810536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antivirulence drugs to target bacterial secretion systems.
    Baron C
    Curr Opin Microbiol; 2010 Feb; 13(1):100-5. PubMed ID: 20079679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving outcomes in the management of Gram-negative bacterial infections in the face of growing antimicrobial resistance.
    Mayor S
    Future Microbiol; 2016 Oct; 11():1223-1226. PubMed ID: 27680185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial: Resistance in gram-negative pathogens: a threat to global health.
    Hanson ND
    Curr Pharm Des; 2013; 19(2):163. PubMed ID: 22920832
    [No Abstract]   [Full Text] [Related]  

  • 38. YopJ Family Effectors Promote Bacterial Infection through a Unique Acetyltransferase Activity.
    Ma KW; Ma W
    Microbiol Mol Biol Rev; 2016 Dec; 80(4):1011-1027. PubMed ID: 27784797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms of bacterial virulence: type III secretion and pathogenicity islands.
    Mecsas JJ; Strauss EJ
    Emerg Infect Dis; 1996; 2(4):270-88. PubMed ID: 8969244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial secrets of secretion: EuroConference on the biology of type IV secretion processes.
    Baron C; OCallaghan D; Lanka E
    Mol Microbiol; 2002 Mar; 43(5):1359-65. PubMed ID: 11918819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.